President and CEO of AFFYMAX, INC. (AFFY, Financial) Arlene Morris sells 101,100 shares of AFFY on 09/28/2009 at an average price of $25 a share.
AFFYMAX INC. is a biopharmaceutical company that is developing a pipeline of synthetic peptide-based drug candidates against clinically validated targets for the treatment of kidney diseases and cancer. Affymax's objective is to discover develop and commercialize novel therapeutics addressing large unmet medical needs. A collaboration of several venture firms created Affymax as an independent company a spin-out from GlaxoSmithKline. Affymax has leveraged its foundation to become a developer of peptide drugs.Their lead productHematide is a synthetic peptide-based erythropoiesis-stimulating agent in clinical development for the treatment of anemia. Hematide is currently entering Phase THREE clinical trials for the treatment of anemia associated with chronic renal failure and is in Phase TWO clinical trials for the treatment of anemia in cancer patients. Affymax, Inc. has a market cap of $452.9 million; its shares were traded at around $23.89 with and P/S ratio of 5.5.
Recent Trades of AFFYMAX, INC. by CEO:
Recent Trades of AFFYMAX, INC. by Directors and Officers:
AFFYMAX INC. is a biopharmaceutical company that is developing a pipeline of synthetic peptide-based drug candidates against clinically validated targets for the treatment of kidney diseases and cancer. Affymax's objective is to discover develop and commercialize novel therapeutics addressing large unmet medical needs. A collaboration of several venture firms created Affymax as an independent company a spin-out from GlaxoSmithKline. Affymax has leveraged its foundation to become a developer of peptide drugs.Their lead productHematide is a synthetic peptide-based erythropoiesis-stimulating agent in clinical development for the treatment of anemia. Hematide is currently entering Phase THREE clinical trials for the treatment of anemia associated with chronic renal failure and is in Phase TWO clinical trials for the treatment of anemia in cancer patients. Affymax, Inc. has a market cap of $452.9 million; its shares were traded at around $23.89 with and P/S ratio of 5.5.
Recent Trades of AFFYMAX, INC. by CEO:
- Sell: President and CEO Arlene Morris sold 6,555 shares of AFFY stock on 09/01/2009 at the average price of $25; the price of the stock has decreased by 4.44% since.
Recent Trades of AFFYMAX, INC. by Directors and Officers:
- Sell: 10% Owner Managers Inc Apax sold 43,401 shares of AFFY stock on 09/16/2009 at the average price of $21.62; the price of the stock has increased by 10.5% since.
- Sell: 10% Owner Partners Europe Managers Apax sold 56,599 shares of AFFY stock on 09/16/2009 at the average price of $21.62; the price of the stock has increased by 10.5% since.
- Sell: 10% Owner Partners Europe Managers Apax sold 169,795 more shares of AFFY stock on 09/14/2009 at the average price of $21; the price of the stock has increased by 13.76% since.
- Sell: 10% Owner Managers Inc Apax sold 130,205 shares of AFFY stock on 09/14/2009 at the average price of $21; the price of the stock has increased by 13.76% since.
- Sell: 10% Owner Managers Inc Apax sold 173,606 more shares of AFFY stock on 09/11/2009 at the average price of $21; the price of the stock has increased by 13.76% since.
